Price (delayed)
$5.75
Market cap
$1.65B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$1.31B
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients
There are no recent dividends present for RXRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.